ACOMPLIA® (RIMONABANT) RECEIVES MARKETING AUTHORISATION IN THE EUROPEAN UNION
First-in-class CB1 blocker approved for the treatment of obese patients, or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaemia
-
-
Lång- och korttidsverkande insulin i jämförande studie: Färre injektioner, färre känningar och stabilare blodsockernivåer med insulin glargin
Behandling med insulin glargin ger låga blodsockernivåer och färre insulinkänningar med en tredjedel så många injektioner som behandling med insulin lispro. Detta visar Apollo-studien som redovisades på den årliga diabeteskongressen, American Diabetes Associations, ADA, som hölls i Washington D.C. i veckan.
-
NEW STUDY SHOWS INSULIN GLARGINE (LANTUS®) AS EFFECTIVE AND BETTER TOLERATED THAN THE PRANDIAL INSULIN LISPRO IN INITIATING INSULIN THERAPY IN TYPE 2 DIABETES
Apollo study shows insulin glargine achieves HbA1c below 7% with less hypoglycemia, 3 times less insulin injections and less self-monitoring than the prandial analog lispro.
-
NEW STUDY SHOWS AN INNOVATIVE MEALTIME INSULIN DOSING ALGORITHM MAY PROVIDE A SAFE AND EFFECTIVE ALTERNATIVE TO CARBOHYDRATE COUNTING FOR PATIENTS WITH TYPE 2 DIABETES
Type 2 Diabetes Patients Using a New Insulin Dosing Strategy Achieved a Mean A1C of 6.6% after 24 Weeks of Combination Therapy with Rapid-Acting Apidra® (insulin glulisine [rDNA origin] injection) and 24-hour Lantus® (insulin glargine [rDNA origin] injection).
-
STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS
Paris, France, June 7, 2006 Sanofiaventis announced today key trial results presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia, regarding the use of Taxotere® (docetaxel) regimens in the treatment of non small cell lung cancer (NSCLC), head and neck cancer and metastatic and adjuvant breast cancer.
-
STUDIES EVALUATING ELOXATIN®-BASED REGIMENS IN GASTROINTESTINAL CANCERS PRESENTED AT THE 42nd ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
Sanofiaventis announced today key results from three studies evaluating Eloxatin® (oxaliplatin injection) in various gastrointestinal tumor types (colorectal, pancreatic and gastric cancers). These results were presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia.
-
Results of a meta-analysis show benefits of Taxotere® (docetaxel) regimens in patients with advanced non-small cell lung cancer (NSCLC)
Sanofi-aventis announced today that a meta-analysis performed on seven clinical trials in patients with advanced non-small cell lung cancer showed that patients receiving Taxotere® (docetaxel) Injection Concentrate had demonstrated overall survival and less febrile neutropenia than those treated with vinca-alkaloid (vinorelbine or vindesine) regimens.
-
Sanofi-aventis stärker sin organisation
Sanofi-aventis befinner sig i en expansiv fas med förberedelser inför lansering av ny produkt och många spännande studier i pipeline. Detta resulterar i en omfattande rekrytering.
-
GENERAL MEETING OF SHAREHOLDERS
The Combined General Meeting of Shareholders of sanofi-aventis was held May 31, 2006.
-
NEW ELOXATIN® AND TAXOTERE® DATA IN SEVERAL TUMOR TYPESTO BE PRESENTED AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
- 430 abstracts from studies involving Taxotere® or Eloxatin® accepted at the meetings scientific sessions -
-
ADJUVANTED FORMULATION OF SANOFI PASTEUR H5N1 PANDEMIC INFLUENZA VACCINE CANDIDATE DEMONSTRATES SIGNIFICANT IMMUNE RESPONSE
Lyon, France May 11, 2006 A study published online in The Lancet on May 11 demonstrated that multiple dosage formulations of a candidate H5N1 influenza vaccine developed by sanofi pasteur were well-tolerated and generated an immune response, with and without adjuvant. Of the formulations being tested, an alum-adjuvanted 30 microgram (µg) dosage generated the most substantive immune response (
-
PLAVIX® (clopidogrel) LAUNCHED IN JAPAN
Paris, France, May 9, 2006 - Sanofi-aventis announced today that PLAVIX® (clopidogrel) has been launched in Japan.
Visa mer
Loading...